1
Country: USA | Funding: $740.5M
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension
2
Country: USA | Funding: $337.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
3
Country: Switzerland | Funding: $101.7M
aktiia makes wristband continuous blood pressure monitoring devices
aktiia makes wristband continuous blood pressure monitoring devices
4
Country: USA | Funding: $100M
Judo Bio develops kidney-delivered oligonucleotide therapies for renal diseases. Its STRIKE (Selectively Targeting RNA Into KidnEy) platform utilizes a proprietary approach based on a natural endogenous mechanism to deliver siRNA drugs to specific kidney cell types. Its initial drug development programs are ligand-siRNA conjugates designed for receptor-mediated uptake by specific kidney cell types, resulting in the suppression of target genes that modify the course of systemic diseases, potentially including inborn errors of metabolism, gout, hypertension, type 2 diabetes, chronic heart failure, nephrolithiasis and other endocrine disorders.
Judo Bio develops kidney-delivered oligonucleotide therapies for renal diseases. Its STRIKE (Selectively Targeting RNA Into KidnEy) platform utilizes a proprietary approach based on a natural endogenous mechanism to deliver siRNA drugs to specific kidney cell types. Its initial drug development programs are ligand-siRNA conjugates designed for receptor-mediated uptake by specific kidney cell types, resulting in the suppression of target genes that modify the course of systemic diseases, potentially including inborn errors of metabolism, gout, hypertension, type 2 diabetes, chronic heart failure, nephrolithiasis and other endocrine disorders.
5
Country: Japan | Funding: ¥13.3B
CureApp is involved in the research and development of prescription and non-prescription digital therapeutics applications. CureApp's prescription DTx app is used for the treatment of hypertension.
CureApp is involved in the research and development of prescription and non-prescription digital therapeutics applications. CureApp's prescription DTx app is used for the treatment of hypertension.
6
Country: USA | Funding: $15.5M
Riva Health is building a cardiology technology app that measures and manages hypertension.
Riva Health is building a cardiology technology app that measures and manages hypertension.
7
Country: India | Funding: $500K
Aarca Research is a healthtech company providing non-invasive diagnostic solutions for chronic diseases. Its product IHRA (Intelligent Health Risk Assessment) is a first-of-its-kind diagnostic method for the risk evaluation of Type 2 Diabetes, Hypertension and Dyslipidemia.
Aarca Research is a healthtech company providing non-invasive diagnostic solutions for chronic diseases. Its product IHRA (Intelligent Health Risk Assessment) is a first-of-its-kind diagnostic method for the risk evaluation of Type 2 Diabetes, Hypertension and Dyslipidemia.
